Outcome of post–liver transplant ischemic and nonischemic biliary stenoses treated with percutaneous interventions: The bologna experience

Emanuela Giampalma, Matteo Renzulli, Cristina Mosconi, Giorgio Ercolani, Antonio Daniele Pinna, Rita Golfieri – 17 October 2011 – In liver transplantation (LT), biliary strictures (BSs) are among the most common complications. The aim of this study was to evaluate the efficacy of percutaneous treatments in the management of post‐LT BSs. Between 1999 and 2007, 48 patients underwent percutaneous treatments for posttransplant BSs.

Liver transplantation in human immunodeficiency virus–infected patients: Procoagulant, but is antithrombotic prophylaxis required?

P. Thomas Cherian, Wesal Alrabih, Abdel Douiri, Alberto Quaglia, Michael A. Heneghan, John O'Grady, Mohamed Rela, Nigel D. Heaton – 17 October 2011 – Liver transplantation (LT) for human immunodeficiency virus (HIV)–positive recipients with end‐stage liver disease has become an accepted practice. However, because these patients are increasingly being recognized as prothrombotic, we reviewed their posttransplant thrombotic complications.

Use of living donor liver transplantation varies with the availability of deceased donor liver transplantation

Parsia A. Vagefi, Nancy L. Ascher, Chris E. Freise, Jennifer L. Dodge, John P. Roberts – 17 October 2011 – The demographics of patients in the United States who undergo living donor liver transplantation (LDLT) versus patients who undergo deceased donor liver transplantation (DDLT) are interesting with respect to the demographics of the donor service areas (DSAs). We examined adult recipients of primary, non–status 1 liver‐only transplants from 2003 to 2009. The likelihood of undergoing LDLT was compared to the likelihood of undergoing DDLT by multivariate logistic regression.

Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation

Benjamin H. Friedman, Joshua H. Wolf, Liqing Wang, Mary E. Putt, Abraham Shaked, Jason D. Christie, Wayne W. Hancock, Kim M. Olthoff – 17 October 2011 – Early allograft dysfunction (EAD) occurring in the first week post‐liver transplantation is associated with increased graft failure and mortality and is believed to be largely due to ischemia/reperfusion injury.

Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

Masanobu Tsuda, Yuki Moritoki, Zhe‐Xiong Lian, Weici Zhang, Katsunori Yoshida, Kanji Wakabayashi, Guo‐Xiang Yang, Toshio Nakatani, John Vierling, Keith Lindor, M. Eric Gershwin, Christopher L. Bowlus – 17 October 2011 – The aim of this study was to determine the safety and potential efficacy of B‐cell depletion with the anti‐CD20 monoclonal antibody rituximab in patients with primary biliary cirrhosis (PBC) and an incomplete response to ursodeoxycholic acid (UDCA).

A phase 2, randomized, double‐blind, placebo‐controlled study of GS‐9450 in subjects with nonalcoholic steatohepatitis

Vlad Ratziu, Muhammad Y. Sheikh, Arun J. Sanyal, Joseph K. Lim, Hari Conjeevaram, Naga Chalasani, Manal Abdelmalek, Anezi Bakken, Christophe Renou, Melissa Palmer, Robert A. Levine, B. Raj Bhandari, Melanie Cornpropst, Wei Liang, Benjamin King, Elsa Mondou, Franck S. Rousseau, John McHutchison, Mario Chojkier – 17 October 2011 – In nonalcoholic steatohepatitis (NASH), the extent of hepatocyte apoptosis correlates with disease severity. Reducing hepatocyte apoptosis with the selective caspase inhibitor GS‐9450 has a potential for altering the course of the liver disease.

Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: Role of biopsy

Thomas Sersté, Vincent Barrau, Violaine Ozenne, Marie‐Pierre Vullierme, Pierre Bedossa, Olivier Farges, Dominique‐Charles Valla, Valérie Vilgrain, Valérie Paradis, Françoise Degos – 17 October 2011 – Liver macronodules, ranging from benign to low‐grade or high‐grade dysplastic nodules (LGDNs/HGDNs) and hepatocellular carcinoma (HCC), may develop during chronic liver diseases (CLDs).

Subscribe to